Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02351752
Other study ID # 2014?851?
Secondary ID
Status Completed
Phase Phase 4
First received January 27, 2015
Last updated December 15, 2015
Start date January 2015
Est. completion date October 2015

Study information

Verified date December 2015
Source Peking University First Hospital
Contact n/a
Is FDA regulated No
Health authority China: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

IgA nephropathy is the most common type of primary glomerulonephritis and might caused by deposition of immune complex containing IgA in mesangium and causing local immune activation. Hydroxychloroquine reduces the activation of dendritic cells and the inflammatory process and showed the potential effect of treatment of patients with IgA nephropathy.

The investigators study will recruite IgA nephropathy patients with proteinuria range from 0.75 to 3.5g/d even after three-month treatment by sufficient ACEi/ARB. The patients were treated with Hydroxychloroquine 300-400mg/d according to eGFR. The proteinuria will recorded every two months and total four months. Then, the drug will be stopped for two months for observation of change of proteinuria.


Description:

Immunoglobulin A (IgA) nephropathy is the most common type of primary glomerulonephritis worldwide. Several studies indicated that 6-43% of IgA nephropathy patients would develop end-stage kidney disease (ESKD) over a period of 10 years. The clinical risk factors for progression are hypertension, protienuria, impaired renal function and histologic lesions at presentation. There is no well accepted optimal therapy for patients with IgA. Current established therapies include full RAS inhibition and optimal blood pressure control for patients with proteinuria and/or hypertension.

Hydroxychloroquine has been used for many years to treat malaria. It is also used to treat systemic lupus erythematosus, rheumatic disorders like rheumatoid arthritis and Sjögren's Syndrome. Recently, several studies found that Hydroxychloroquine could reduce the risk of ESRD in patients with lupus nephrits. The mechanism of the treatment wasn't well known so far. Some investigators found that Hydroxychloroquine increases lysosomal pH in antigen presenting cells. In inflammatory conditions, it blocks toll-like receptors on plasmacytoid dendritic cells (PDCs). Toll-like receptor 9 (TLR 9), which recognizes DNA-containing immune complexes, leads to the production of interferon and causes the dendritic cells to mature and present antigen to T cells. Hydroxychloroquine, by decreasing TLR signaling, reduces the activation of dendritic cells and the inflammatory process.

The pathogenesis of IgA nephropathy included the deposition of immune complex containing IgA in mesangium and causing local immune activation and injury to kidney. Therefore, Hydroxychloroquine might have the potential effect of anti-inflammation in patients with IgA nephropathy, reduced the proteinuria and had the renal protect effect.

Our study will recruite IgA nephropathy patients with proteinuria range from 0.75 to 3.5g/d even after three-month treatment by sufficient ACEi/ARB. The patients were treated with Hydroxychloroquine 300-400mg/d according to eGFR. The proteinuria will recorded every two months and total four months. Then, the drug will be stopped for two months for observation of change of proteinuria.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date October 2015
Est. primary completion date October 2015
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

1. primary IgA nephopathy

2. age 18-75 years

3. proteinuria range from 0.75 to 3.5g/d even after three-month treatment by sufficient ACEi/ARB

4. eGFR>30ml/min/1.73m2

Exclusion Criteria:

1. immune suppressive agent in recent one years

2. crescent glomerulonephritis, might use immune suppressive agent

3. chronic hepatic disease

4. myocardial infarction

5. malignant hypertension

6. stroke

7. malignant tumor

8. retinopathy

9. other contraindication of Hydroxychloroquine

10. pregnancy and breastfeeding women

11. life expectancy for less than 6 months

12. in other clinical trials

13. not suitable for the study judged by investigator

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
Hydroxychloroquine Sulfate
Hydroxychloroquine Sulfate: 0.1 Tid(eGFR 30-59);0.2 Bid (eGFR>60)

Locations

Country Name City State
China Peking University First Hospital BeiJing Beijing

Sponsors (1)

Lead Sponsor Collaborator
LLiu

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary proteinuia total four months(proteinic will recorded every 2 months ) No
See also
  Status Clinical Trial Phase
Completed NCT03643965 - Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy Phase 3
Recruiting NCT04557462 - A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy Phase 3
Active, not recruiting NCT04541043 - Efficacy and Safety in Patients With Primary IgA Nephropathy Who Have Completed Study Nef-301 (Nefigard-OLE) Phase 3
Recruiting NCT05847920 - Efficacy and Safety of SHR-2010 Injection in the Treatment of Primary IgA Nephropathy Phase 2
Recruiting NCT02765594 - Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy Phase 4
Not yet recruiting NCT02712697 - Integrative Medicine of IgA Nephropathy N/A
Completed NCT04887532 - A Trial of HR19042 Capsule in Healthy Chinese Subjects Phase 1
Not yet recruiting NCT06137768 - A Trial of HRS-5965 Tablets in Primary IgA Nephropathy Phase 2
Completed NCT04014335 - A Study to Evaluate the Effectiveness and Safety of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Adult Participants With Primary IgA Nephropathy Phase 2
Completed NCT01738035 - The Effect of Nefecon® in Patients With Primary IgA Nephropathy at Risk of Developing End-stage Renal Disease Phase 2
Recruiting NCT05797610 - A Study to Evaluate the Efficacy and Safety of RO7434656 in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression Phase 3